[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"skin-cancer-non-melanoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:skin-cancer-non-melanoma":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100613404","prospective-collection-of-clinical-data-and-human-body-material-hbm-of-cutaneous-melanoma-non-melanoma-patients-and-healthy-controls-biobank-huidkanker-100613404",false,"NCT07266142","Prospective Collection of Clinical Data and Human Body Material (HBM) of Cutaneous Melanoma, Non Melanoma Patients and Healthy Controls. Biobank Huidkanker","Prospective Collection of Clinical Data and Human Body Material (HBM): Blood (Serum, Plasma, DNA) and Tissue of Cutaneous Melanoma, Non Melanoma Patients and Healthy Controls. Biobank Huidkanker","Inclusion Criteria:\n\n* Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures\n* Adult subjects (\\>18 years of age) at time of enrolment.\n* Subjects diagnosed with cutaneous melanoma, Non-melanoma skin cancer or healthy controls.\n* Adult subjects able and willing to provide informed consent.\n\nExclusion Criteria:\n\n* Subjects unable or not willing to provide informed consent.\n* Pregnancy (or willing to become pregnant) is NOT an exclusion criteria (unless specified in the respective satellite protocols.","ALL","18 Years",{"count":19,"type":20},7500,"ESTIMATED","OBSERVATIONAL","The goal of this clinical trial is to set up a prospective, fit-for-purpose collection of human body material (HBM)-blood (serum, plasma, DNA) and tissue-and standardized clinical data of patients with cutaneous melanoma, non-melanoma skin cancer and healthy controls.\n\nThe main questions it aims to answer are:\n\n* To create a biobank with samples of human body material (HBM): blood (serum\u002Fplasma\u002FDNA) and tissue and clinical data of patients with cutaneous melanoma, non-melanoma and helathy controls.\n* To support future research questions (after specific approval of the Ethics Committee) by using the biobank (through satellite protocols).\n\nIf there is a comparison group: Not applicable (umbrella protocol for collection only).\n\nParticipants will:\n\n* Share demographics, medical and surgical history, risk factors.\n* Complete Cancer Worry Scale questionnaire.\n* Provide biological samples:\n\n  * Blood samples (serum, plasma, DNA).\n  * Tissue samples (residual tissue or additional biopsy if consented).",[24,25],"Skin Cancer, Non-Melanoma","Skin Cancer Melanoma",[27,28,29],"Prospective Collection","Skin Cancer","Human Body Material","RECRUITING","2026-06-10",{"date":33,"type":34},"2026-06-12","ACTUAL",{"date":36,"type":34},"2025-11-17",{"date":38,"type":20},"2051-01",{"name":40,"class":41},"Universitaire Ziekenhuizen KU Leuven","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":59,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":42},"100500267","impact-of-hypofractionated-radiotherapy-strategy-after-surgery-of-skin-carcinomas-in-older-patients-100500267","NCT05794035","Impact of Hypofractionated Radiotherapy Strategy After Surgery of Skin Carcinomas in Older Patients","Impact of Hypofractionated Radiotherapy Strategy After Surgery of Skin Carcinomas in Older Patients IMPACTE-01","IMPACTE-01","Inclusion Criteria:\n\n* Patients aged ≥ 70 years\n* OMS 0-3\n* Pathology confirmation of invasive SCC or BCC\n* At least one of high-risk factors for recurrence (R0 but close margins, location\u002Fsize, microscopic perineural invasion, recurrent primary disease, immunosuppression, thickness including Breslow and Clark level, poorly-moderately differentiated)\n* No indication of regional nodal RT\n* No prior RT to the treated site\n* Written consent from patient or his\u002Fher legal representative, trustworthy person or family member if the person is physically unable to give his or her written consent\n* Life expectancy ≥ 6 months, as clinically estimated by the investigator in charge of enrolment\n* No contraindication for surgery and RT after multidisciplinary board meeting evaluation\n* Affiliated to a social security scheme\n\nExclusion Criteria:\n\n* Macroscopic incomplete resection of the primary tumor (≥ R1)\n* Patient with severe dementia not allowing follow-up\n* Any psychological, familial, sociological, geographical or logistical reasons that would prevent participation to surveillance during treatment and follow-up\n* Other active cancers in treatment\n* Participation in another interventional study (therapeutic trial interfering with the study's endpoints)\n* Patient on AME (state medical aid)\n* Persons deprived of their liberty by a judicial or administrative decision","70 Years",{"count":53,"type":20},303,"INTERVENTIONAL",[56],"NA","Non-melanoma skin cancer (NMSC) incidence as well as morbidity rates are high in older patients. Surgery is the standard of care. About 5 to 10% of NMSC present high-risk clinico-pathologic features that can increase risk of local recurrence (LR).\n\nAdjuvant radiation therapy (ART) is often discussed regarding the risk of local recurrence. Despite the lack of high level evidence, ART is indicated in patients according to unfavorable prognostic factors. ART benefit is generally questioned in regard to the potential degradation of the patient's quality of life (QoL). Currently there is no prospective trial or recommendations that take into account geriatric patients' evaluation and profiles during the management of NMSC. In addition, there is no data that could help to define the subgroup of elderly patients who will benefit from ART in tumors with unfavorable prognostic factors.\n\nIn terms of ART, multiple fractionation schedules are available, ranging from standard fractionation (45-60Gy in 5-6 weeks) to the extreme hypofractionation (HF) delivering 16-18Gy in one fraction.\n\nIn routine practice, HF is mainly preferred in elderly patients for more convenience by reducing the number of transports and increase health related quality of life (HRQoL). However, there is no data on the fragility profiles of these patients, nor validating any HF schedule in terms of efficacy, acute toxicity, cosmetic results, and impact on HRQoL.\n\nthe main ain objective is to evaluate the comparative efficacy of two modalities of Radiotherapy over surgery alone on local tumor control in older patients with Non Melanoma Skin Cancer (NMSC) In current practice, adjuvant radiotherapy is discussed regarding the risk of local recurrence as determined by the existence (or not) of unfavorable prognostic factors. The proposed study will include R0-high risk of CBC and CEC of the skin in elderly patients. There is no risk regarding the design of the trial as the last will respond to two important unknown questions regarding the utility of RT and its fractionation in this population. Moreover, it is an excellent opportunity to collect prospectively geriatric evaluation and HRQoL data that are lacking in the literature for skin cancers. No constraints are seen neither in the design, nor in the potential recruitments.",[24],[60,61,62],"Non Melanoma Skin Cancer","Adjuvant radiation therapy","older patient","2023-11-27",{"date":65,"type":34},"2023-11-30",{"date":67,"type":34},"2023-10-17",{"date":69,"type":20},"2028-03-01",{"name":71,"class":41},"Assistance Publique - Hôpitaux de Paris"]